Led by Top Oncologist Professor Wu Yilong Expected to Commence Phase III Clinical Trial in 2H2019. Demonstrates Strong R&D Capability Solidifies Oncology Drug Development Strategy
Sihuan Pharm
Tidak Ada Postingan Lagi.
Tidak ada lagi halaman untuk dimuat.